Objectives: To evaluate the association between C-reactive protein (CRP) and 10-year risk of cardiovascular (CV) events using the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA), based on conventional and RA-specific risk factors but not CRP, in RA patients without previous cardiovascular events. Methods: ERS-RA was calculated in 1,251 "Cardiovascular Obesity and Rheumatic Disease Study (CORDIS)" database patients [(age 60.4(9.3) years; 78% female; disease duration, 11.6(8) years; CDAI, 9(9); CRP, 6.8(12) mg/L].Results: The mean (SD) 10-year risk of CV events was 12.9% (10). After adjusting for the use of DMARDs and biologics, CRP concentrations were significantly associated with 10-year risk of CV events (coefficient=0.005 for each 10 mg/L CRP increment; 95%CI 0.000-0.111; p = 0.047). In mediation analysis, the association between CRP and ERS-RA was not explained by disease activity.Conclusion: In a large cohort of RA patients without previous cardiovascular events, a 20 mg/L increase in CRP concentrations was associated with a 1% increase in 10-year risk of CV events. This suggests that actively tar-geting residual inflammatory risk beyond conventional and RA-specific risk factors might further reduce CV event rates in RA patients.

C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis

Cauli, Alberto
Membro del Collaboration Group
;
Piga, Matteo
Ultimo
Supervision
2022-01-01

Abstract

Objectives: To evaluate the association between C-reactive protein (CRP) and 10-year risk of cardiovascular (CV) events using the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA), based on conventional and RA-specific risk factors but not CRP, in RA patients without previous cardiovascular events. Methods: ERS-RA was calculated in 1,251 "Cardiovascular Obesity and Rheumatic Disease Study (CORDIS)" database patients [(age 60.4(9.3) years; 78% female; disease duration, 11.6(8) years; CDAI, 9(9); CRP, 6.8(12) mg/L].Results: The mean (SD) 10-year risk of CV events was 12.9% (10). After adjusting for the use of DMARDs and biologics, CRP concentrations were significantly associated with 10-year risk of CV events (coefficient=0.005 for each 10 mg/L CRP increment; 95%CI 0.000-0.111; p = 0.047). In mediation analysis, the association between CRP and ERS-RA was not explained by disease activity.Conclusion: In a large cohort of RA patients without previous cardiovascular events, a 20 mg/L increase in CRP concentrations was associated with a 1% increase in 10-year risk of CV events. This suggests that actively tar-geting residual inflammatory risk beyond conventional and RA-specific risk factors might further reduce CV event rates in RA patients.
2022
C-reactive protein
Cardiovascular risk score
Inflammation
Myocardial infarction
Stroke
C-Reactive Protein
Female
Heart Disease Risk Factors
Humans
Male
Middle Aged
Receptors, Immunologic
Risk Factors
Antirheumatic Agents
Arthritis, Rheumatoid
Biological Products
Cardiovascular Diseases
File in questo prodotto:
File Dimensione Formato  
C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis - Erre 2022.pdf

Solo gestori archivio

Tipologia: versione editoriale
Dimensione 614.3 kB
Formato Adobe PDF
614.3 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
C-reactive protein and 10-year risk - copertina IRIS.pdf

accesso aperto

Tipologia: versione pre-print
Dimensione 554.62 kB
Formato Adobe PDF
554.62 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/349176
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 15
social impact